Harbeck, NNHarbeckRastogi, PPRastogiMartin, MMMartinTolaney, S MS MTolaneyShao, Z MZ MShaoFasching, P AP AFaschingCHIUN-SHENG HUANGJaliffe, G GG GJaliffeTryakin, AATryakinGoetz, M PM PGoetzRugo, H SH SRugoSenkus, EESenkusTesta, LLTestaAndersson, MMAnderssonTamura, KKTamuraDel Mastro, LLDel MastroSteger, G GG GStegerKreipe, HHKreipeHegg, RRHeggSohn, JJSohnGuarneri, VVGuarneriCortés, JJCortésHamilton, EEHamiltonAndré, VVAndréWei, RRWeiBarriga, SSBarrigaSherwood, SSSherwoodForrester, TTForresterMunoz, MMMunozShahir, AAShahirSan Antonio, BBSan AntonioNabinger, S CS CNabingerToi, MMToiJohnston, S R DS R DJohnstonO'Shaughnessy, JJO'Shaughnessy2022-04-152022-04-1520210923-7534https://scholars.lib.ntu.edu.tw/handle/123456789/604458Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of the prespecified primary outcome analysis and an additional follow-up analysis.enCDK4/6; Ki-67; abemaciclib; adjuvant; early breast cancer[SDGs]SDG3journal article10.1016/j.annonc.2021.09.015346567402-s2.0-85118361413WOS:000721610600014https://api.elsevier.com/content/abstract/scopus_id/85118361413